Aethlon Medical, Inc. AEMD
Set alert
5.44 USD -0.08 -1.45%
At close · Oct 30
5.31 -0.13 -2.39%
After hours · Oct 30, 4:38 PM ET
5.15 Day range 5.48
1.43 52-week range 27.15
- YTD
- -60.72%
- 1 year
- -79.96%
- Open
- 5.30
- Prev close
- 5.52
- Mkt cap
- 8.73M
- Vol
- 27.67K
- Avg vol
- 2.57M
- EPS
- -32.97
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 5.15
- High
- 5.48
- Forward P/E
- -0.86
- Beta
- 1.75
- Short ratio
- 0.98
- Inst. own
- 3.09%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 12, 2025
- 50-d avg
- 0.4028
- 200-d avg
- 0.6753
- 1y target
- 3.85
Key statistics
- Market cap
- 7.95M
- Enterprise value
- -2.65M
- Trailing P/E
- 0.00
- Forward P/E
- -0.86
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.26
- EPS (TTM)
- -2.79
- Beta
- 1.75
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -5.21M
- Total cash
- 9.07M
- Total debt
- 869.95K
- Return on equity
- -105.38%
- Shares outstanding
- 13.96M
- Short % of float
- 2.07%
- 50-day average
- 0.4028
- 200-day average
- 0.6753
Analyst view
Consensus: none
Price target (mean) 3.85 -29.2% downside
Now 5.44
- Target (low)
- 0.70
- Target (mean)
- 3.85
- Target (high)
- 7.00
Ratings (0m) 2 1 buy · 1 hold · 0 sell
- Strong buy1
- Buy0
- Hold1
- Sell0
- Strong sell0
Next earnings
Feb 12, 2025
Expected Feb 12, 2025. Consensus EPS estimate -0.20333.
Financials — quick view
AEMD Revenue — quarterly 0
AEMD Net income — quarterly -1.55M
AEMD EPS — quarterly -4.02
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 12, 2025 | Dec 1, 2024 | -0.22 | — | — | — |
| Nov 13, 2024 | Sep 1, 2024 | -0.20 | -0.20 | 0.00 | 0.00% |
| Aug 14, 2024 | Jun 1, 2024 | -0.44 | -0.34 | +0.10 | +22.73% |
| Jun 27, 2024 | Mar 1, 2024 | -1.18 | -0.91 | +0.27 | +22.88% |
| Feb 14, 2024 | Dec 1, 2023 | -1.23 | -1.37 | -0.14 | -11.38% |
| Nov 14, 2023 | Sep 1, 2023 | -1.35 | -1.22 | +0.13 | +9.63% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 24, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Mar 4, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Oct 24, 2023 | HC Wainwright & Co. | main | Buy | Buy |
About Aethlon Medical, Inc.
Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device for cancer and life-threatening viral infections and use in organ transplantation. The company was founded in 1984 and is based in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- aethlonmedical.com
News
- Aethlon Stock Pulls Back: What's Going On?
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- Aethlon Medical Q1 2027 Earnings Call Transcript
- Aethlon Medical, Oklo, CID HoldCo, Xenon Pharmaceuticals and Moderna: Why These 5 Stocks Are on Investors' Radars Today
- Crude Oil Down 1%; US Pending Home Sales Rise 0.3% In August
- 12 Health Care Stocks Moving In Thursday's Intraday Session
- Nasdaq Jumps 400 Points; US Weekly Jobless Claims Fall
- Aethlon Medical Pivots to Biotechnology with All-Stock Merger
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Aethlon Medical To Merge With North Immunology; AEMD Holders To Retain ~4.75% Of Combined Company, With North Immunology Stockholders To Own ~95.25%; NewCo Expected To Have Pro Forma Equity Value Of ~$346.5M; Oversubscribed $180M Private Placement Expected To Fund NewCo Operations Into H2 2028
Your note
Sign in to keep a note on AEMD — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BROENNIMAN EDWARD G | Director | Stock Award(Grant) | Apr 15, 2024 | 45,464 |
| GIKAKIS NICOLAS | Director | Stock Award(Grant) | Apr 15, 2024 | 46,574 |
| ROSSETTI ANGELA | Director | Stock Award(Grant) | Apr 15, 2024 | 200,543 |
| SHAH CHETAN S | Director | Stock Award(Grant) | Apr 15, 2024 | 44,532 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| UBS Group AG | 1.56% | 218,253 | 124.30K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.70% | 98,394 | 56.03K | Sep 29, 2024 |
| Vanguard Group Inc | 0.15% | 21,230 | 12.09K | Sep 29, 2024 |
| Baader Bank Aktiengesellschaft | 0.12% | 17,329 | 9.87K | Sep 29, 2024 |
| Two Sigma Investments, LP | 0.11% | 15,436 | 8.79K | Sep 29, 2024 |
| Two Sigma Securities, LLC | 0.10% | 13,738 | 7.82K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.53% | 73,859 | 42.06K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.15% | 21,224 | 12.09K | Sep 29, 2024 |
| Fidelity Series Total Market Index Fund | 0.12% | 17,412 | 9.92K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.02% | 2,534 | 1.44K | Oct 30, 2024 |